Cancer Injection Shrinks Tumours, But Access Will Take Time

A targeted cancer injection has produced strong results in people with advanced head and neck cancer after other treatments had stopped working.

Some patients had major tumour shrinkage. In some cases, doctors could no longer see the tumour after treatment.

That is a serious result.

It does not mean the treatment is ready for everyone. It does not mean every cancer patient can now get an injection instead of chemotherapy. It means a difficult group of patients may have a new treatment route where there were very few options before.

The treatment is called amivantamab. It is given as an injection under the skin.

It is already used in some lung cancer treatment, but this trial looked at a different cancer group: people with recurrent or metastatic head and neck squamous cell carcinoma.

That means the cancer had either come back or spread.

The patients in this trial had already received immunotherapy and platinum-based chemotherapy. Their cancer had still continued to grow.

That detail is important. This was not a trial in newly diagnosed patients. It was a trial in people whose cancer had already resisted major treatment.

What the trial found

The trial included 102 patients.

Doctors saw tumours shrink or disappear in 43 of them. That is about 42%.

Of those patients, 15 had what doctors call a complete response. This means the visible tumour disappeared on assessment.

Another 28 had a partial response. This means the tumour shrank significantly.

For patients with advanced cancer and few remaining treatment choices, those numbers are meaningful.

The treatment also worked quickly for some people. The median time to first response was about 6.6 weeks. That means many of the patients who responded showed signs of improvement within weeks rather than years.

But the longer-term numbers are more cautious.

The median time before the cancer grew again was 6.8 months. Median overall survival after starting treatment was 12.5 months.

Those figures show why the result should be taken seriously, but also why it should not be treated as a cure.

What complete response means

The phrase tumour disappeared sounds final.

In medicine, it is more careful than that.

A complete response means doctors can no longer detect the tumour on scans or clinical assessment. It does not prove that every cancer cell has gone. Some complete responses last. Some cancers return later.

That is why researchers keep measuring survival, tumour growth, side effects and duration of response.

A strong scan result is important. It is not the same as long-term proof.

Why this treatment is different

Amivantamab targets cancer in more than one way.

It blocks EGFR, a protein that can help cancer cells grow. It blocks MET, a pathway cancer cells can use to resist treatment. It can also help the immune system attack the tumour.

That combination is why the treatment has attracted attention.

The injection method also matters. A treatment given under the skin can be quicker and easier than a long intravenous infusion. For very ill patients, that difference can affect quality of life as well as hospital time.

The treatment still has side effects. Reported problems included rash, nail inflammation, skin reactions and administration-related reactions. In the trial report, about 8% of patients stopped treatment because of treatment-related side effects.

So this is not a simple or risk-free treatment. It is a possible extra route for patients with a hard cancer and limited options.

The likely timeline

There are two timelines to understand.

The first is the faster one: approval for the specific group tested in the trial.

Johnson & Johnson has submitted the treatment for US regulatory review in this head and neck cancer setting. If regulators accept the evidence, the treatment could become available sooner for patients similar to those in the trial: people with recurrent or metastatic head and neck cancer after previous treatment has failed.

That would still be a specific approval. It would not automatically apply to all head and neck cancer patients.

The second timeline is slower: wider use earlier in treatment.

A larger Phase 3 trial, called OrigAMI-5, is now under way. It is testing amivantamab as part of first-line treatment for recurrent or metastatic head and neck cancer. That trial is listed as running until June 2029.

That means wider routine use is likely to need several more years of evidence, unless regulators approve a narrower use earlier.

For the NHS, there is another step. A medicine normally needs UK regulatory approval and NICE assessment before it becomes routinely available. NICE looks at clinical benefit, safety and cost-effectiveness. If NICE recommends a treatment, the NHS must fund it for eligible patients.

So even a strong trial result does not mean immediate NHS access.

What people should take from this

This is a good news story, but it needs accurate language.

The trial showed strong tumour shrinkage in a group of patients whose cancer had already resisted major treatment. Some patients had no visible tumour left after treatment. Responses often appeared within weeks.

At the same time, the median time before the cancer grew again was under seven months. Larger trials are still needed. Regulators still have to make decisions. NHS access would need approval and funding decisions.

The best way to read the story is this:

A targeted injection has shown real promise for people with advanced head and neck cancer after standard treatment has failed. It may give doctors another option in a situation where options are often running out. The result is important, but it is still part of the treatment-development process, not the end of it.